Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy-Reference-Cited by-同舟云学术

Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy

Published:1999-04-01 Issue:2 Volume:4 Page:87-94
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Bookman Michael A.¹

Affiliation:

1. Medical Gynecologic Oncology, Medical Information Management, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Abstract

Abstract Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse with development of drug-resistant disease. Topotecan is the most extensively studied agent currently available for management of recurrent ovarian cancer and has been approved by the FDA for that particular indication. Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.4-2-87

Reference31 articles.

1. Treatment of recurrent ovarian cancer: increasing options—“recurrent” results;Ozols;J Clin Oncol,1997

2. Chemotherapy of advanced ovarian cancer;McGuire;Semin Oncol,1998

3. Second-line chemotherapy for recurrent carcinoma of the ovary;Thigpen;Cancer,1993

4. Second-line platinum-therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J Clin Oncol,1991

5. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials;Blackledge;Br J Cancer,1989

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse;Journal of Ovarian Research;2023-10-28

2. Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer;Cells;2022-02-26

3. Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis;Biomarker Insights;2022-01

4. Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer;PeerJ;2021-06-17

5. Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer;Journal of Ovarian Research;2021-01-11